medigraphic.com

2022, Number 4

<< Back

Rev Hematol Mex 2022; 23 (4)

Diffuse non-Hodgkin lymphoma of extranodal large cells in a young patient with symptoms of splenic infarction

Chazaro-Rocha EF, Granados-Espinosa IB, Zúñiga-Perea V, Torres-Fierro A

Language: Spanish
References: 28
Page: 260-367
PDF size: 398.82 Kb.


ABSTRACT

Background: Diffuse large B-cell non-Hodgkin’s lymphoma is the most frequent subtype of non-Hodgkin’s lymphoma in the world, representing 30-40% of cases. Splenic infarcts manifest with abdominal pain syndrome and B symptoms.
Clinical case: A 35-year-old male patient who began with abdominal pain in epigastrium of intensity 10/10, leukocytosis of 20,000, amylase and lipase in normal range. Pancreatitis was suspected in USG. The CT scan showed a splenic and liver abscess, free fluid in abdominal cavity and pleural effusion. Patient had splenic infarction, the histopathological study after splenectomy reported: cells infiltration with atypical lymphoid appearance; immunohistochemistry: CD20+, Cd3-, CD15-, CD 30-, IPI 1, Ann Arbor I. Treatment with R-CHOP for 6 cycles was started, presenting complete remission.
Conclusions: The treatment of choice is R-CHOP and in case of spleen involvement splenectomy improves progression, when accompanied by rituximab.


REFERENCES

  1. Rappaport H. Tumors of the hematopoeitic system. WashingtonDC: Armed Forces Institute Pathology, 1996.

  2. Teras LR, Desantis CE, Cerhan JR, et al. 2016 US lymphoidmalignancy statistics by World Health Organization subtypes.CA Cancer J Clin 2016; 66 (6): 443-59. doi: 10.3322/caac.21357.

  3. Ollila TA, Olszewski AJ. Extranonal diffuse large B cell lymphoma:molecular features, prognosis, and risk of centralnervous system recurrence. Curr Treat Options Oncol 2018;19 (8): 38. doi: 10.1007/s11864-018-0555-8.

  4. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodalinvolvement are prognostic in patients. With diffuse largeB-cell Lymphoma in the rituximab era: An analysis of theSurveillance, Epidemiology and End Results database. AmJ Hematol 2014; 89 (3): 310-315. doi: 10.1002/ajh.23638.

  5. Aubrey-Brassler FK, Sowers N. 613 cases of splenic rupturewithout risk factors or previously diagnosed diseasea systematic review. BMC Emerg Med 2012; 14: 11. doi:10.1186/1471-227X-12-11.

  6. Biswas S, Keddington J, McClanathan J. Large B-celllymphoma presenting as acute abdominal pain andspontaneous splenic rupture; a case report and review ofrelevant literature. World J Emerg Surg 2006; 1: 35. doi:10.1186/1749-7922-1-35.

  7. Cunningham D, Hawkes EA, Jack A, Qian W, et al. Rituximabplus cyclophosphamide, doxorubicin, vincristine, and prednisolonein patients with newly diagnosed diffuse large B-cellnon-Hodgkin lymphoma: A phase 3 comparison of dose intensificationwith 14-day versus 21-day cycles. Lancet 2013;381: 1817-1826. doi: 10.1016/S0140-6736(13)60313-X.

  8. Pfreundschuh M, Kuhnt E,Trumper L, Osterborg A, et al.CHOP like chemotherapy with or without rituximab inyoung patients with good-prognosis diffuse large-B-celllymphoma: 6-year results of an open-label randomisedstudy of the MabThera International Trial (MInT) Group.Lancet Oncol 2011; 12: 1013-1022. doi: 10.1016/S1470-2045(11)70235-2.

  9. Recher C, Coiffier B, Haioun C, Molina T, et al. Intensifiedchemotherapy with ACVBP plus rituximab versus standardCHOP plus rituximab for the treatment of diffuse largeB-cell lymphoma (LNH03-2B): an open-label randomisedphase 3 trial. Lancet 2011; 378: 1858-1867. doi: 10.1016/S0140-6736(11)61040-4.

  10. Schmitz N, Nickelsen M, Ziepert M, Haenel M, et al. Conventionalchemotherapy (CHOEP-14) with rituximab orhigh-dose chemotherapy (Mega-CHOEP) with rituximabfor young, high-risk patients with a aggressive B-celllymphoma: an open-label, randomised, phase 3 trial(DSHNHL2002-1). Lancet Oncol 2012; 13: 1250-1259. doi:10.1016/S1470-2045(12)70481-3.

  11. Chappuis K, Simoens C, Smets D, Duttmann R, Mendes daCosta P. Spontaneous rupture of the spleen in relation toa non Hodgkin lymphoma. Acta Chir Belg 2007; 107 (4):446-8. doi: 10.1080/00015458.2007.11680094.

  12. Antopolsy M, Hiller N, Salameh S, Goldshtein B, StalnikowiczR. Splenic Infarction: 10 years of experience. Am JEmerg Medicine 2009; 27 (3): 262-265. doi: 10.1016/j.ajem.2008.02.014.

  13. Jaroch MT, Broughan TA, Hermann RE. The natural historyof splenic infarction Surgery 1986; 100 (4): 743-750.

  14. Goerg C, Schewrk WB. Splenic infarction: sonographicpatterns, diagnosis, follow-up, and complications.Radiology 1990; 174: 803-807. doi: 10.1148/radiology.174.3.2406785.

  15. O’Keefe JH, Holmes DR, Schaff HV, Sheedy PF, Edwards WD.Thromboembolic splenic infarction. Mayo Clin Proc 1986;61 (12): 967-972. doi: 10.1016/s0025-6196(12)62638-x.

  16. Nores MP, Phillips EH, Morgenstenrn L, Hiatt J.R. Theclinical spectrum of splenic infarction. Am Surg 1998; 64(2): 182-188.

  17. Brett AS, Azizzadeh N, Miller EM, et al. Assessment of clinicalconditions associated with splenic infarction in adultpatients. JAMA 2020;180 (8): 1125-1127. doi:10.1001/jamainternmed.2020.2168.

  18. Smalls N, Obirieze A, Ehanire I. El impacto de la coagulopatíaen las lesiones esplénicas traumáticas. Soy J Surg 2015; 210 (4): 724-9.

  19. Soyuncu S, Bektas F, Cete Y. Traditional Kehr’s sign: Leftshoulder pain related to splenic abscess. Ulus TravmaAcil Cerrahi Derg 2012; 18 (1): 87-88. doi: 10.5505/tjtes.2011.04874.

  20. Kaniappan K, Seong-Lim CT, Woon PC, Non-traumaticsplenic rupture – a rare first presentation of diffuse largeB-cell lymphoma and review of the literature. BMC Cancer2018; 18: 779. doi: 10.1186/s12885-018-4702-1.

  21. Byrd KP, Vontela NR, Mccullar B, Martin MG. Multidatabasedescription of primary splenic diffuse large Bcelllymphoma. Anticancer Res 2017; 37: 6839-6843. doi:10.21873/anticanres.12145.

  22. Renzulli P, Hostettler A, Schoepfer AM, Gloor B, Candinas D.Systematic review of atraumatic splenic rupture. Br J Surg2009; 96: 1114-21. doi: 10.1002/bjs.6737.

  23. Griffiths JD, Ding JC, Juneja SK, Thomas RJ, MArtin JJ, CooperIA. Pathological rupture of the spleen in transformingnon Hodgkin lymphoma. Med J Aust 1986; 144 (3): 146-7.doi: 10.5694/j.1326-5377.1986.tb112245.x.

  24. Gennai A, Basili G, Lorenzetti L, Crocetti G, Filidei M, OrciuolaE, Prosperi V, Goletti O. Spontaneous rupture of thespleen in non-Hodgkin lymphoma: a case report. Chir Ital2008; 60 (5): 739-44.

  25. Chan VS, Hei MY, Kwong YL, Yin-Lam SH. Non-traumaticsplenic rupture secondary to haemorrahagic infarct ondiffuse large B-cell lymphoma, BMJ Case Rep 2019; 12:e229052. doi: 10.1136/bcr-2018-229052.

  26. National Comprehensive Cancer Network. B-cell lymphomasVersion 4.2019. Retrieved From https://www.nccn.org/professionals/physician_gls/pdf/b-cell_lymphomas.pdf.

  27. Bairey O, Schvidel L, Perry C, Dann EJ, Ruchlemer R, TadmorT, Goldshmidth N. Characteristics of primary. Splenicdiffuse large B-cell lymphoma and role of splenectomy inimproving survival. Cancer 2015; 121 (17): 2909-2916. doi:10.1002/cncr.29487.

  28. Morel P, Dupriez B, Gosselin B, Fenaux P, Estienne MH, Facon T,Jouet JP and Bauter F: Role of early splenectomy in malignantlymphomas with prominent splenic involvement (primary lymphomasof the spleen). A study of 59 cases. Cancer 1993; 71 (1):207-215. doi: 10.1002/1097-0142(19930101)71:1<207::aidcncr2820710132> 3.0.co;2-0.




2020     |     www.medigraphic.com